Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial)

Schmid, Andrea; Friess, Dorothea; Mansouri Taleghani, Behrouz; Keller, Peter; Müller, Beatrice Ursula; Baerlocher, Gabriela M.; Leibundgut, Kurt; Pabst, Thomas (2014). Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leukemia & lymphoma, 56(3), pp. 608-614. Informa Healthcare 10.3109/10428194.2014.927454

[img] Text
GMB_BM_PAV-trial Leukemia and Lymphoma 2015.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.
Download (5MB)

Current practice in Switzerland for the mobilization of autologous stem cells in patients with myeloma is combining vinorelbine chemotherapy and granulocyte-colony stimulating factor (G-CSF) cytokine stimulation. We prospectively investigated adding intravenous plerixafor to the vinorelbine/G-CSF combination (VGP), and compared it with vinorelbine/plerixafor (VP) and G-CSF/plerixafor (GP) combinations. In a final cohort (VP-late), plerixafor was given on the first day of CD34 + cells increasing to > 15 000/mL peripheral blood. Four consecutive cohorts of 10 patients with myeloma were studied. We observed that intravenously administered plerixafor can be safely combined with vinorelbine/G-CSF. VGP was superior in mobilizing peripheral stem and progenitor cells compared to the three double combinations (VP, GP and VP-late), and GP mobilized better than VP. Our data indicate that the triple combination of VGP is an efficient strategy to collect autologous CD34 + cells, with G-CSF contributing predominantly in this concept. Plerixafor can be safely added to G-CSF and/or vinorelbine chemotherapy.

Item Type:

 Journal Article (Original Article)

Division/Institute:

 04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hämatologie / Onkologie (Pädiatrie)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hämatologie / Onkologie (Pädiatrie)

UniBE Contributor:

 Friess, Dorothea, Mansouri Taleghani, Behrouz, Keller, Peter, Müller, Beatrice Ursula, Baerlocher, Gabriela M., Leibundgut, Kurt, Pabst, Thomas Niklaus

Subjects:

 600 Technology > 610 Medicine & health

ISSN:

 1042-8194

Publisher:

 Informa Healthcare

Language:

 English

Submitter:

 Anette van Dorland

Date Deposited:

 10 Feb 2015 16:37

Last Modified:

 02 Mar 2023 23:25

Publisher DOI:

 10.3109/10428194.2014.927454

PubMed ID:

 24884311

Uncontrolled Keywords:

 Clinical results, myeloma, stem cell mobilization

BORIS DOI:

 10.7892/boris.62871

URI:

 https://boris.unibe.ch/id/eprint/62871

Actions (login required)

Edit item Edit item
Provide Feedback